Premium
Feasibility of reduced‐intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome‐positive acute lymphoblastic leukemia
Author(s) -
Yamada Kayo,
Yasui Masahiro,
Kondo Osamu,
Sato Maho,
Sawada Akihisa,
Kawa Keisei,
Inoue Masami
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24507
Subject(s) - medicine , imatinib , hematopoietic stem cell transplantation , lymphoblastic leukemia , oncology , transplantation , philadelphia chromosome , chemotherapy , stem cell , leukemia , adverse effect , chromosomal translocation , genetics , myeloid leukemia , biology , gene
Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph + ALL) in children is one of the highest‐risk ALL groups. Improved outcome in combination with imatinib has been reported. However, intensive chemotherapy or myeloablative conditioning followed by hematopoietic stem cell transplantation (HSCT) can be associated with significant adverse late effects. We report a case series of five children with Ph + ALL underwent reduced‐intensity allogeneic HSCT (RIST) after induction and consolidation in chemotherapy combined with imatinib. Four of the five patients remain first complete remission for a median of 3.1 years after RIST. These results are preliminary, but suggest the feasibility and effectiveness of RIST with imatinib. Pediatr Blood Cancer 2013;60:E60–E62. © 2013 Wiley Periodicals, Inc.